Ret finger protein-like 3 promotes tumor cell growth by activating telomerase reverse transcriptase expression in human lung cancer cells

Oncotarget

Volumn 5, Issue 23, 2014, Pages 11909-11923

  Chen, Wangbing ^a,d   Lu, Jianjun ^c   Qin, Yu ^b   Wang, Jingshu ^a   Tian, Yun ^a   Shi, Dingbo ^a   Wang, Shusen ^a   Xiao, Yao ^b   Dai, Meng ^b   Liu, Lu ^b   Wei, Guo ^b   Wu, Taihua ^b   Jin, Bilian ^b   Xiao, Xiangsheng ^a   Kang, Tie Bang ^a   Huang, Wenlin ^a,e   Deng, Wuguo ^a,e  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b DALIAN MEDICAL UNIVERSITY   (China)

^c SUN YAT SEN UNIVERSITY   (China)

^d HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^e Guangzhou Double Bioproduct Inc   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING PROTEIN; RET FINGER PROTEIN LIKE 3; RNA DIRECTED DNA POLYMERASE; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; TELOMERASE REVERSE TRANSCRIPTASE; UNCLASSIFIED DRUG; CARRIER PROTEIN; RFPL3 PROTEIN, HUMAN; TELOMERASE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CANCER INHIBITION; CANCER PROGNOSIS; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG TARGETING; ENZYME ACTIVATION; ENZYME ACTIVITY; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG CARCINOGENESIS; LYMPH NODE METASTASIS; MALE; MOUSE; NON SMALL CELL LUNG CANCER; NONHUMAN; OVERALL SURVIVAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN EXPRESSION; TUMOR XENOGRAFT; UPREGULATION; ANIMAL; BIOSYNTHESIS; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; KAPLAN MEIER METHOD; LUNG TUMOR; METABOLISM; MORTALITY; NUDE MOUSE; PATHOLOGY; PHYSIOLOGY; POLYMERASE CHAIN REACTION; PROPORTIONAL HAZARDS MODEL; TISSUE MICROARRAY; TUMOR CELL LINE; WESTERN BLOTTING; XENOGRAFT;

ANIMALS; BLOTTING, WESTERN; CARCINOMA, NON-SMALL-CELL LUNG; CARRIER PROTEINS; CELL LINE, TUMOR; CHROMATIN IMMUNOPRECIPITATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION, NEOPLASTIC; HETEROGRAFTS; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MICE; MICE, NUDE; POLYMERASE CHAIN REACTION; PROPORTIONAL HAZARDS MODELS; TELOMERASE; TISSUE ARRAY ANALYSIS; TRANSFECTION;

EID: 84919953117     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2557     Document Type: Article

References (42)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA: a cancer journal for clinicians. 2013; 63:11-30.
2. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Okinaga S, Hirano H, Yoshimori K, Harada T, Ogura T, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. The New England journal of medicine. 2010; 362:2380-2388.
3. Shaw AT, Yeap BY, Mino-Kenudson M, Digumarthy SR, Costa DB, Heist RS, Solomon B, Stubbs H, Admane S, McDermott U, Settleman J, Kobayashi S, Mark EJ, Rodig SJ, Chirieac LR, Kwak EL, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2009; 27:4247-4253.
4. Nebhan C, Pao W. Further advances in genetically informed lung cancer medicine. Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer. 2013; 8:521-522.
5. Pao W, Girard N. New driver mutations in non-small-cell lung cancer. The lancet oncology. 2011; 12:175-180.
6. Remon J, Moran T, Reguart N, Majem M, Carcereny E, Lianes P. Beyond EGFR TKI in EGFR-mutant Non-Small Cell Lung Cancer patients: Main challenges still to be overcome. Cancer treatment reviews. 2014; 40:723-729.
7. Shaw AT, Kim DW, Nakagawa K, Seto T, Crino L, Ahn MJ, De Pas T, Besse B, Solomon BJ, Blackhall F, Wu YL, Thomas M, O'Byrne KJ, Moro-Sibilot D, Camidge DR, Mok T, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. The New England journal of medicine. 2013; 368:2385-2394.
8. Ruden M, Puri N. Novel anticancer therapeutics targeting telomerase. Cancer treatment reviews. 2013; 39:444-456.
9. Shay JW, Keith WN. Targeting telomerase for cancer therapeutics. British journal of cancer. 2008; 98:677-683.
10. Agrawal A, Dang S, Gabrani R. Recent patents on antitelomerase cancer therapy. Recent patents on anti-cancer drug discovery. 2012; 7:102-117.
11. Tian X, Chen B, Liu X. Telomere and telomerase as targets for cancer therapy. Applied biochemistry and biotechnology. 2010; 160:1460-1472.
12. Blackburn EH. Telomerase and Cancer: Kirk A. Landon-AACR prize for basic cancer research lecture. Molecular cancer research: MCR. 2005; 3:477-482.
13. Shay JW, Wright WE. Telomerase therapeutics for cancer: challenges and new directions. Nature reviews Drug discovery. 2006; 5:577-584.
14. Kyo S, Takakura M, Fujiwara T, Inoue M. Understanding and exploiting hTERT promoter regulation for diagnosis and treatment of human cancers. Cancer science. 2008; 99:1528-1538.
15. Yu K, Zheng B, Han M, Wen JK. ATRA activates and PDGF-BB represses the SM22alpha promoter through KLF4 binding to, or dissociating from, its cis-DNA elements. Cardiovascular research. 2011; 90:464-474.
16. Lu B, Lee J, Nie X, Li M, Morozov YI, Venkatesh S, Bogenhagen DF, Temiakov D, Suzuki CK. Phosphorylation of human TFAM in mitochondria impairs DNA binding and promotes degradation by the AAA+ Lon protease. Molecular cell. 2013; 49:121-132.
17. Ramakrishnan P, Clark PM, Mason DE, Peters EC, Hsieh-Wilson LC, Baltimore D. Activation of the transcriptional function of the NF-kappaB protein c-Rel by O-GlcNAc glycosylation. Science signaling. 2013; 6:ra75.
18. Badding MA, Lapek JD, Friedman AE, Dean DA. Proteomic and functional analyses of protein-DNA complexes during gene transfer. Molecular therapy: the journal of the American Society of Gene Therapy. 2013; 21:775-785.
19. Powers NR, Eicher JD, Butter F, Kong Y, Miller LL, Ring SM, Mann M, Gruen JR. Alleles of a polymorphic ETV6 binding site in DCDC2 confer risk of reading and language impairment. American journal of human genetics. 2013; 93:19-28.
20. Bu Y, Gao L, Gelman IH. Role for transcription factor TFII-I in the suppression of SSeCKS/Gravin/Akap12 transcription by Src. International journal of cancer Journal international du cancer. 2011; 128:1836-1842.
21. Picard C, Pellicelli M, Taheri M, Lavoie JF, Doucet R, Wang D, Bernard L, Bouhanik S, Lavigne P, Moreau A. Nuclear accumulation of prohibitin 1 in osteoarthritic chondrocytes down-regulates PITX1 expression. Arthritis and rheumatism. 2013; 65:993-1003.
22. Deng WG, Wu KK. Regulation of inducible nitric oxide synthase expression by p300 and p50 acetylation. J Immunol. 2003; 171:6581-6588.
23. Deng WG, Tang ST, Tseng HP, Wu KK. Melatonin suppresses macrophage cyclooxygenase-2 and inducible nitric oxide synthase expression by inhibiting p52 acetylation and binding. Blood. 2006; 108:518-524.
24. Deng WG, Zhu Y, Wu KK. Role of p300 and PCAF in regulating cyclooxygenase-2 promoter activation by inflammatory mediators. Blood. 2004; 103:2135-2142.
25. Bonnefont J, Nikolaev SI, Perrier AL, Guo S, Cartier L, Sorce S, Laforge T, Aubry L, Khaitovich P, Peschanski M, Antonarakis SE, Krause KH. Evolutionary forces shape the human RFPL1,2,3 genes toward a role in neocortex development. American journal of human genetics. 2008; 83:208-218.
26. Assou S, Boumela I, Haouzi D, Monzo C, Dechaud H, Kadoch IJ, Hamamah S. Transcriptome analysis during human trophectoderm specification suggests new roles of metabolic and epigenetic genes. PloS one. 2012; 7:e39306.
27. Bonnefont J, Laforge T, Plastre O, Beck B, Sorce S, Dehay C, Krause KH. Primate-specific RFPL1 gene controls cell-cycle progression through cyclin B1/Cdc2 degradation. Cell death and differentiation. 2011; 18:293-303.
28. Deng WG, Jayachandran G, Wu G, Xu K, Roth JA, Ji L. Tumor-specific activation of human telomerase reverses transcriptase promoter activity by activating enhancerbinding protein-2beta in human lung cancer cells. The Journal of biological chemistry. 2007; 282:26460-26470.
29. Aragaki M, Takahashi K, Akiyama H, Tsuchiya E, Kondo S, Nakamura Y, Daigo Y. Characterization of a cleavage stimulation factor, 3' pre-RNA, subunit 2, 64 kDa (CSTF2) as a therapeutic target for lung cancer. Clinical cancer research: an official journal of the American Association for Cancer Research. 2011; 17:5889-5900.
30. Daigo Y, Nakamura Y. From cancer genomics to thoracic oncology: discovery of new biomarkers and therapeutic targets for lung and esophageal carcinoma. General thoracic and cardiovascular surgery. 2008; 56:43-53.
31. Kim MP, Chen Y, Bekele BN, Lopez A, Khanna A, Chen JQ, Spitz MR, Behrens C, Solis L, Wismach M, Ji L, Wistuba II, Roth JA, Katz RL. Activating enhancer-binding protein-2beta nucleolar localization predicts poor survival after stage I non-small cell lung cancer resection. The Annals of thoracic surgery. 2011; 92:1044-1050.
32. Grass B, Wachtel M, Behnke S, Leuschner I, Niggli FK, Schafer BW. Immunohistochemical detection of EGFR, fibrillin-2, P-cadherin and AP2beta as biomarkers for rhabdomyosarcoma diagnostics. Histopathology. 2009; 54:873-879.
33. Rudzinski ER, Anderson JR, Lyden ER, Bridge JA, Barr FG, Gastier-Foster JM, Bachmeyer K, Skapek SX, Hawkins DS, Teot LA, Parham DM. Myogenin, AP2beta, NOS-1, and HMGA2 Are Surrogate Markers of Fusion Status in Rhabdomyosarcoma: A Report From the Soft Tissue Sarcoma Committee of the Children's Oncology Group. The American journal of surgical pathology. 2014; 38:654-659.
34. Wachtel M, Rakic J, Okoniewski M, Bode P, Niggli F, Schafer BW. FGFR4 signaling couples to Bim and not Bmf to discriminate subsets of alveolar rhabdomyosarcoma cells. International journal of cancer Journal international du cancer. 2014.
35. Wang L, Soria JC, Kemp BL, Liu DD, Mao L, Khuri FR. hTERT expression is a prognostic factor of survival in patients with stage I non-small cell lung cancer. Clinical cancer research: an official journal of the American Association for Cancer Research. 2002; 8:2883-2889.
36. Lantuejoul S, Soria JC, Moro-Sibilot D, Morat L, Veyrenc S, Lorimier P, Brichon PY, Sabatier L, Brambilla C, Brambilla E. Differential expression of telomerase reverse transcriptase (hTERT) in lung tumours. British journal of cancer. 2004; 90:1222-1229.
37. Zhu CQ, Cutz JC, Liu N, Lau D, Shepherd FA, Squire JA, Tsao MS. Amplification of telomerase (hTERT) gene is a poor prognostic marker in non-small-cell lung cancer. British journal of cancer. 2006; 94:1452-1459.
38. Zhang G, Wang G, Wang S, Li Q, Ouyang G, Peng X. Applying proteomic methodologies to analyze the effect of hexamethylene bisacetamide (HMBA) on proliferation and differentiation of human gastric carcinoma BGC-823 cells. The international journal of biochemistry & cell biology. 2004; 36:1613-1623.
39. Kato T, Shimono Y, Hasegawa M, Jijiwa M, Enomoto A, Asai N, Murakumo Y, Takahashi M. Characterization of the HDAC1 complex that regulates the sensitivity of cancer cells to oxidative stress. Cancer research. 2009; 69: 3597-3604.
40. Zhao X, Yue W, Zhang L, Ma L, Jia W, Qian Z, Zhang C, Wang Y. Downregulation of PAX6 by shRNA inhibits proliferation and cell cycle progression of human non-small cell lung cancer cell lines. PloS one. 2014; 9:e85738.
41. Xiao X, Shi D, Liu L, Wang J, Xie X, Kang T, Deng W. Quercetin suppresses cyclooxygenase-2 expression and angiogenesis through inactivation of P300 signaling. PloS one. 2011; 6:e22934.
42. Shi D, Xie F, Zhang Y, Tian Y, Chen W, Fu L, Wang J, Guo W, Kang T, Huang W, Deng W. TFAP2A regulates nasopharyngeal carcinoma growth and survival by targeting HIF-1alpha signaling pathway. Cancer Prev Res (Phila). 2014; 7:266-277.